Tiburio Therapeutics has appointed Nerissa Kreher to the newly created position of chief medical officer. Kreher held that post at her previous company, Avrobio (NASDAQ: AVRO). Her experience also includes positions at Shire, Zafgen (NASDAQ: ZFGN), and Alexion Pharmaceuticals (NASDAQ: ALXN). In January, Tibiurio launched from biotech accelerator Cydan, backed by $31 million in funding. Cambridge, MA-based Tiburio is developing treatments for rare neuroendocrine tumors and rare endocrine diseases.